Equities

Marizyme Inc

MRZM:QBB

Marizyme Inc

Actions
  • Price (USD)0.093
  • Today's Change0.00 / 0.00%
  • Shares traded420.00
  • 1 Year change-25.60%
  • Beta0.4198
Data delayed at least 15 minutes, as of May 31 2024 14:30 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Marizyme, Inc. is a medical technology company. The Company is focused on cardiac and surgical care by delivering innovative solutions for coronary artery bypass graft (CABG) surgery and other surgical procedures. Its product DuraGraft, is a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, thereby reducing the incidence and complications of graft failure and improving clinical outcomes post bypass surgery. The Company’s product under development includes MATLOC and MAR-FG-001. MATLOC is a lab-on-chip digital screening and diagnostic device platform being developed for quantitative chronic kidney disease (CKD) assessment. The MAR-FG-001 is a tumescent solution base for fat grafting procedures that is used for plastic and cosmetic surgeries in which fat is transferred from one area of the body to another to correct a defect, replace injured tissue, or to make cosmetic enhancements.

  • Revenue in USD (TTM)645.81k
  • Net income in USD-65.35m
  • Incorporated2007
  • Employees11.00
  • Location
    Marizyme Inc555 HERITAGE DRIVE, SUITE 205JUPITER 33458United StatesUSA
  • Phone+1 (561) 935-9955
  • Fax+1 (770) 720-1335
  • Websitehttps://marizyme.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Galera Therapeutics Inc0.00-45.75m11.70m7.00---------0.9971-0.99710.00-2.480.00----0.00-115.30-83.69-142.79-97.54-----------6.499.23------5.05---29.84--
Transcode Therapeutics Inc0.00-17.06m11.75m10.00--2.25-----206.36-206.360.000.78930.00----0.00-264.82-133.14-721.90-181.26-----------148.050.00-------5.59------
Enzolytics Inc0.00-119.19k11.80m2.00---------0.106-0.1060.00-1.040.00-------369.52-----------------4.30-----100.00---9.35------
Sunshine Biopharma Inc26.74m-4.09m11.87m44.00--0.0251--0.4439-13.35-13.3576.9624.960.90813.1311.58607,722.50-13.88-101.52-17.99-137.0433.1535.47-15.29-165.333.23--0.00--454.42--83.15--110.99--
Pioneer Green Farms Inc40.05k-537.65k11.94m6.00------298.10-0.0228-0.02280.0017-0.02430.06641.01--6,675.00-89.14------26.59---1,342.45--0.0099-155.9214.08------35.41------
Avalo Therapeutics Inc1.45m-142.88m12.08m19.00------8.33-318.69-318.693.02-97.750.0181--3.2576,315.79-178.64-99.64---154.4254.9084.69-9,853.73-613.58---0.2415-----89.34-22.8324.28---22.48--
Mira Pharmaceuticals Inc0.00-12.36m12.09m3.00--3.83-----0.8276-0.82760.000.21360.00----0.00-587.64---1,721.90-------------2.630.00-------69.77------
Guardion Health Sciences Inc12.06m-5.12m12.24m9.00--3.58--1.01-4.00-4.009.492.660.97182.635.961,340,280.00-41.26-77.90-47.92-86.5543.4342.45-42.46-176.936.49-4.240.00--10.8567.03101.00---58.56--
Marizyme Inc645.81k-65.35m12.26m11.00------18.98-1.43-1.430.0142-0.03540.02131.568.7258,710.00-215.30-59.02-351.53-64.4770.8770.38-10,118.60-9,435.920.0458-0.65651.36--176.5999.98-71.22------
Lotus Pharmaceuticals Inc70.79m1.72m12.39m233.000.08310.00133.210.17510.05530.05532.563.580.632137.2717.85303,836.901.5522.841.7126.4035.1041.622.4519.930.442830.800.05160.0028.7131.70-12.2251.1170.48--
ELEVAI Labs Inc2.18m-4.62m12.47m18.00--4.60--5.71-0.2665-0.26650.1260.1435------121,351.70--------67.84---211.42--1.80--0.00--123.50---138.94------
Plus Therapeutics Inc (USA)6.08m-11.77m12.61m20.00------2.07-3.19-3.191.67-1.130.5724----304,200.00-110.75-59.18---133.04-----193.49-470.45--------2,093.30-5.8934.32--3.77--
GlucoTrack Inc0.00-8.74m12.71m6.00--33.02-----1.87-1.870.000.07030.00----0.00-520.58-94.01-2,110.63-142.35-------10,447.96----0.3415-------60.02------
Organovo Holdings Inc242.00k-19.09m12.77m15.00--1.56--52.78-2.17-2.170.02750.62830.0143--4.4412,100.00-112.40-51.24-123.59-54.90-----7,886.36-1,269.78----0.00---75.33-39.60-50.76--5.99--
Shineco Inc5.62m-14.34m12.89m87.00--0.3582--2.29-3.98-2.321.365.580.06640.481.4564,633.68-19.79-12.77-38.28-16.8412.7725.88-298.09-102.060.4842-8.140.3908-----58.35-33.86------
Data as of May 31 2024. Currency figures normalised to Marizyme Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.